Cardiovascular Effects of GLP-1 Receptor Activation
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 329 participants.
Also called NCT03101930
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose basic science
- Phase
- Phase 4
- Enrolled
- 329 participants
- Registry
-
NCT03101930
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03101930. Randomized; quadruple masking; primary purpose basic science. Start 2017-05-01 (actual); primary completion 2021-06-24 (actual). Results posted on 2022-08-16.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Cardiovascular Effects of GLP-1 Receptor Activation
- Condition
- Obesity
- Condition
- PreDiabetes
- Intervention (Drug)
- Liraglutide
- Intervention (Drug)
- Sitagliptin
- Intervention (Other)
- hypocaloric diet
- Intervention (Drug)
- Placebos
- Intervention (Drug)
- Exendin (9-39)
- Lead sponsor
- Vanderbilt University Medical Center
- Collaborator
- American Heart Association
Record details
- Record id
cardio:ct-nct03101930- Content hash
aecb57b61d5b937cd618d6547c5d58d40421c79a35758704c23f1087f8c6467e